Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial

This secondary analysis of a randomized clinical trial investigates the relative effectiveness and safety of the sodium-glucose cotransporter-2 inhibitor dapagliflozin for Black vs White patients with chronic kidney disease (CKD) in North and South America.

Detalles Bibliográficos
Autores principales: Vart, Priya, Jongs, Niels, Wheeler, David C., Heerspink, Hiddo J. L., Langkilde, Anna Maria, Chertow, Glenn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140802/
https://www.ncbi.nlm.nih.gov/pubmed/37103935
http://dx.doi.org/10.1001/jamanetworkopen.2023.10877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140802/
https://www.ncbi.nlm.nih.gov/pubmed/37103935
http://dx.doi.org/10.1001/jamanetworkopen.2023.10877

Ejemplares similares